Skip to main content

Table 4 Prognostic factors for distant disease-free survival: univariate analysis

From: Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study

 

N

5-Year DDFS (%) (95 % CI)

HR (95 % CI)

p-valuea

Age

  < 35

30

82.6 [68.2–100]

1

 

  ≥ 35

726

93.3 [91.2–95.4]

0.5 [0.2–1.3]

0.1223

SBR Grade

 1–2

462

96 [94–98]

1

 

 3

285

87.4 [82.9–92.1]

2.8 [1.6–4.9]

0.0002

Pathological tumor size

 pT1

391

93.6 [90.9–96.5]

1

 

 pT2

320

92.3 [88.9–95.7]

1.2 [0.7–2]

 

 pT3-T4

36

88.2 [78–99.8]

1.6 [0.6–4.7]

0.6395

PVI

 No

558

94.2 [92–96.5]

1

 

 Yes

178

88.8 [83.5–94.5]

2.2 [1.3–4]

0.0042

Hormone receptors

 Negative

208

88 [83–93.4]

1

 

 Positive

526

94.7 [92.5–96.9]

0.6 [0.3–1]

0.049

HER2

 Negative

507

93.2 [90.5–95.9]

1

 

 Positive

96

95.7 [91–100]

0.9 [0.3–2.2]

0.7719

IHC subtypes

 Luminal A

289

96.8 [94.5–99.2]

1

 

 Luminal B/HER2-negative

82

85.5 [76.3–95.8]

4.6 [1.8–11.7]

 

 Luminal B/HER2-positive

58

100 [100–100]

1.2 [0.2–5.5]

 

 HER2

37

89 [77.6–100]

2.9 [0.8–11.1]

 

 Triple-negative

127

89 [82.5–96]

3.3 [1.3–8.2]

0.0059

  1. HR hazard ratio, PVI peritumor vascular invasion
  2. aunadjusted log-rank test